Chloropyramine hydrochloride (CAS 6170-42-9)
See product citations (1)
QUICK LINKS
Chloropyramine hydrochloride is a compound that functions as a histamine H1 receptor antagonist. It acts by competitively inhibiting the binding of histamine to its receptor, thereby preventing the activation of the receptor and subsequent signaling cascades. Chloropyramine Hydrochloride targets and blocks the H1 receptor, which is involved in mediating allergic responses and inflammatory processes. By interfering with the histamine-receptor interaction, Chloropyramine hydrochloride effectively mitigates the physiological effects of histamine, such as vasodilation, increased vascular permeability, and smooth muscle contraction. This mechanism of action may be a useful for investigating the role of histamine in various biological processes and for studying the pharmacology of H1 receptor antagonists. Its ability to block histamine signaling provides insights into the molecular pathways underlying allergic reactions and inflammatory conditions.
Chloropyramine hydrochloride (CAS 6170-42-9) References
- Report of an anaphylactoid and an anaphylactic reaction to ketorolac in two pediatric surgical patients. | Castillo-Zamora, C., et al. 2006. Ther Drug Monit. 28: 458-62. PMID: 16778734
- Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. | Kurenova, EV., et al. 2009. J Med Chem. 52: 4716-24. PMID: 19610651
- Targeting focal adhesion kinase in neuroblastoma. | Gillory, L. and Beierle, EA. 2010. Anticancer Agents Med Chem. 10: 714-21. PMID: 21269252
- Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma. | Stewart, JE., et al. 2015. Mol Carcinog. 54: 9-23. PMID: 23868727
- The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth. | Kurenova, E., et al. 2013. Oncotarget. 4: 1632-46. PMID: 24142503
- Allergic reaction to the tetracycline component of Ledermix paste: a case report. | Kaufman, AY., et al. 2014. Int Endod J. 47: 1090-7. PMID: 24456195
- Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. | Wilton, J., et al. 2016. Eur J Drug Metab Pharmacokinet. 41: 55-67. PMID: 25377246
- Enhancing As(V) adsorption and passivation using biologically formed nano-sized FeS coatings on limestone: Implications for acid mine drainage treatment and neutralization. | Liu, J., et al. 2017. Chemosphere. 168: 529-538. PMID: 27852449
- Acquired Ulcero-Mutilating Bilateral Acro-Osteopathy (Bureau-Barrière Syndrome). | Tchernev, G., et al. 2017. Open Access Maced J Med Sci. 5: 558-560. PMID: 28785364
- Allopurinol-Induced Toxic Epidermal Necrolysis. | Buenrostro-Rubio, I., et al. 2019. Drug Saf Case Rep. 6: 8. PMID: 31549231
- Hypernatremia-induced Neurologic Complications After Hepatic Hydatid Cyst Surgery: Pretreat to Prevent. | Kuzmanovska, B., et al. 2019. Med Arch. 73: 356-358. PMID: 31819311
- Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer. | Kandil, SB., et al. 2020. Molecules. 25: PMID: 32751931
- Progression of primarily untreated desomorphine drug induced jaw osteonecrosis: A case report. | Ramishvili, N., et al. 2022. Spec Care Dentist.. PMID: 36482761
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Chloropyramine hydrochloride, 1 g | sc-234345 | 1 g | $20.00 |